Premium
Prevalence of venous thromboembolism at pretreatment screening and associated risk factors in 2086 patients with gynecological cancer
Author(s) -
Tasaka Nobutaka,
Minaguchi Takeo,
Hosokawa Yoshihiko,
Takao Wataru,
Itagaki Hiroya,
Nishida Keiko,
Akiyama Azusa,
Shikama Ayumi,
Ochi Hiroyuki,
Satoh Toyomi
Publication year - 2020
Publication title -
journal of obstetrics and gynaecology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 50
eISSN - 1447-0756
pISSN - 1341-8076
DOI - 10.1111/jog.14233
Subject(s) - medicine , endometrial cancer , asymptomatic , ovarian cancer , cancer , cervical cancer , gynecology , pulmonary embolism , carcinoma , risk factor , cervix , obstetrics
Aim Postoperative pulmonary embolism can be a fatal surgical complication and is thought to occur secondary to asymptomatic venous thromboembolism (VTE) that exists preoperatively in some patients. The purpose of this study was to clarify the frequency and risk factors of pretreatment VTE in gynecological cancer patients. Methods This study investigated 2086 patients with gynecological cancer (cervix, n = 754; endometrium, n = 862; ovary, n = 470) who underwent initial treatment between 2004 and 2017. Pretreatment VTE screening was performed with D‐dimer (DD) levels in these patients. Based on this, the associated risk factors were retrospectively analyzed. Results Pretreatment VTE was discovered in 7.3% of patients with cervical cancer, 11.5% of those with endometrial cancer and 27.0% of those with ovarian cancer. Significant independent risk factors were: age greater than or equal to 60 years and tumor long diameter greater than or equal to 40 mm for cervical cancer; age greater than or equal to 60 years, stage III/IV advanced disease, clear cell carcinoma and tumor long diameter greater than or equal to 60 mm for endometrial cancer; and age greater than or equal to 60 years, clear cell carcinoma and massive ascites for ovarian cancer. Conclusion Pretreatment asymptomatic VTE is very frequent in gynecological cancer patients. It may be beneficial to consider measuring DD or performing venous ultrasonography in patients with the above risk factors.